Government-Owned Inventions; Availability for Licensing, 44754-44755 [E8-17508]

Download as PDF 44754 Federal Register / Vol. 73, No. 148 / Thursday, July 31, 2008 / Notices Licensing Contact: Adaku Nwachukwu, J.D.; 301/435–5560; madua@mail.nih.gov. Collaborative Research Opportunity: The National Cancer Institute, Center for Cancer Research, Laboratory of Molecular Pharmacology, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize inhibitors of TyrosylDNA phosphodiesterase (Tdp1). Please contact John D. Hewes, PhD at 301–435– 3121 or hewesj@mail.nih.gov for more information. Dated: July 22, 2008. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E8–17506 Filed 7–30–08; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: jlentini on PROD1PC65 with NOTICES SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/ 496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. Methods for Promoting Stem Cell Proliferation and Survival Description of Technology: Regenerative medicine has the potential to treat numerous human diseases and afflictions including neurodegenerative disorders and spinal cord injury that are typically insidious and worsen over VerDate Aug<31>2005 15:53 Jul 30, 2008 Jkt 214001 time. This technology consists of a promising treatment method that coaxes stem cells into a state that promotes survival and proliferation. Two critical elements of this approach involve identifying the target niche and determining the pharmacological agents that can be used to promote stem cell regeneration. Specifically, this technology consists of a method to activate the endogenous neural stem cells (NSCs) to promote their survival and yield using angiopoietin-2 and a cocktail of ligands and growth factors. This method has demonstrated that it can significantly improve the yield of stem cell cultures in vitro and stimulate behavioral recovery in a model of Parkinson’s disease in vivo. This method is applicable to a variety of stem cell types including embryonic stem cells, adult spinal cord cells, and pericyctes from blood vessels. Possible Applications: • Method for culturing stem cells for optimal regeneration. • Treatment of neurological diseases and disorders such as Parkinson’s disease, stroke, diabetes-related neuropathies, and spinal cord. • Diagnostic assays to determine proliferation or inhibition of stem cells. Development Status: Pre-clinical. Inventors: Andreas AndroutsellisTheotokis and Ronald D.G. McKay (NINDS). Relevant Publication: A Androutsellis-Theotokis, RR Leker, F Soldner, DJ Hoeppner, R Ravin, SW Poser, MA Rueger, SK Bae, R Kittappa, RD McKay. Notch signaling regulates stem cell numbers in vitro and in vivo. Nature. 2006 Aug 17;442(7104):823– 826. Patent Status: U.S. Provisional Application No. 60/965,094 filed 16 Aug 2007 (HHS Reference No. E–182– 2007/0–US–01) Licensing Status: Available for licensing. Licensing Contact: Fatima Sayyid, M.H.P.M.; 301–435–4521; Fatima.Sayyid@nih.hhs.gov Collaborative Research Opportunity: The National Institute of Neurological Disorders and Stroke is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize agents with activity on proliferation and/or differentiation of stem cells. Please contact Laurie Arrants at 301–435–3112 or ArrantsL@ninds.nih.gov or Martha Lubet at 301–435–3120 or lubetm@mail.nih.gov for more information. PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 Treatment of Alcoholism by Inhibition of the Neuropeptide Y Receptor Description of Technology: Aversive or anticraving medications are currently used to supplement behavioral treatment of alcohol dependence. However, there is a need for developing more effective medications than those available. Neuropeptide Y (NPY) is a neurotransmitter known for increasing appetite and possibly having a role in alcohol preference and dependence. This is likely to be mediated by activation of the post-synaptic NPY–Y1 receptor, but developing molecules suitable for human therapeutics that activate that receptor represents a major challenge. Researchers at the NIH have now shown that administering antagonists of the presynaptic Y2 receptor of NPY decreases alcohol consumption and may be a valuable new treatment for alcoholism. Applications: Treatment of alcohol dependence. Market: In the United States, 17.6 million people—about l in every 12 adults—abuse alcohol or are alcohol dependent. It is estimated that on any given day, more than 700,000 people in the United States receive alcoholism treatment. Consequently, billions of dollars are spent in the treatment, prevention, and support of persons suffering from alcoholism. Moreover, the economic loss attributed to alcohol abuse and alcoholism is in the trillions. Development Status: Early stage. Inventors: Markus Heilig (NIAAA) et al. Publications: 1. R Rimondini et al. Suppression of ethanol self-administration by the neuropeptide Y (NPY) Y2 receptor antagonist BIIE0246: Evidence for sensitization in rats with a history of dependence. Neurosci Lett. 2005 Feb 28;375(2):129–133. 2. A Thorsell et al. Blockade of central neuropeptide Y (NPY) Y2 receptors reduces ethanol self-administration in rats. Neurosci Lett. 2002 Oct 25;332(1):1–4. Patent Status: U.S. Patent Application 10/492,785 filed 17 May 2004 (HHS Reference No. E–101–2004/0–US–03); Swedish Patent Application 0103476–8 filed 18 Oct 2001 (HHS Reference No. E–101–2004/0–SE–01) Licensing Status: Available for licensing. Licensing Contact: Norbert Pontzer, JD, PhD; 301–435–5502; pontzern@mail.nih.gov. Collaborative Research Opportunity: The National Institute on Alcohol Abuse and Alcoholism, Laboratory of Clinical and Translational Studies is seeking E:\FR\FM\31JYN1.SGM 31JYN1 Federal Register / Vol. 73, No. 148 / Thursday, July 31, 2008 / Notices statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize antagonism of presynaptic NPY Y2 receptors for treatment of alcohol dependence. Please contact Peter B. Silverman at psilverm@mail.nih.gov for more information. Dated: July 22, 2008. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E8–17508 Filed 7–30–08; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the Center for Scientific Review Special Emphasis Panel, July 23, 2008, 8 a.m. to July 24, 2008, 6 p.m., National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 which was published in the Federal Register on July 1, 2008, 78 FR 37469. The meeting will be held August 14, 2008 to August 15, 2008. The meeting time and location remains the same. The meeting is closed to the public. Dated: July 23, 2008. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E8–17518 Filed 7–30–08; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health jlentini on PROD1PC65 with NOTICES Center for Scientific Review; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which VerDate Aug<31>2005 15:53 Jul 30, 2008 Jkt 214001 would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel; Mosquito Vectors. Date: August 19, 2008. Time: 1 p.m. to 3 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Fouad A. El-Zaatari, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3206, MSC 7808, Bethesda, MD 20814–9692, (301) 435–1149, elzaataf@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Musculoskeletal Tissue/Cell Biology. Date: August 20, 2008. Time: 1:15 p.m. to 3 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: John P. Holden, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4211, MSC 7814, Bethesda, MD 20892, 301–496– 8551, holdenjo@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Nursing Science. Date: August 29, 2008. Time: 2 p.m. to 4 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Ann Hardy, DRPH, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3158, MSC 7770, Bethesda, MD 20892, (301) 435– 0695, hardyan@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Multiscale Models of the Physiome. Date: September 17, 2008. Time: 8 a.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: The Carlyle Suites, 1731 New Hampshire Avenue, NW., Washington, DC 20009. Contact Person: Malgorzata Klosek, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4188, MSC 7849, Bethesda, MD 20892, (301) 435– 2211, klosekm@csr.nih.gov. Name of Committee: Musculoskeletal, Oral and Skin Sciences Integrated Review Group; Oral, Dental and Craniofacial Sciences Study Section. Date: September 23–24, 2008. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. PO 00000 Frm 00054 Fmt 4703 Sfmt 4703 44755 Place: The Westin Washington, DC City Center, 1400 M Street, NW., Washington, DC 20005. Contact Person: Tamizchelvi Thyagarajan, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4016K, MSC 7814, Bethesda, MD 20892, 301–451– 1327, tthyagar@csr.nih.gov. Name of Committee: Digestive Sciences Integrated Review Group; Xenobiotic and Nutrient Disposition and Action Study Section. Date: September 24, 2008. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817. Contact Person: Patricia Greenwel, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2174, MSC 7818, Bethesda, MD 20892, 301–435– 1169, greenwep@csr.nih.gov. Name of Committee: Integrative, Functional and Cognitive Neuroscience Integrated Review Group; Auditory System Study Section. Date: September 24–25, 2008. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: One Washington Circle Hotel, One Washington Circle, Washington, DC 20037. Contact Person: Lynn E. Luethke, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5166, MSC 7844, Bethesda, MD 20892, (301) 435– 1018, luethkel@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Pathophysiological Basis of Mental Disorders and Addictions. Date: September 25, 2008. Time: 8 a.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Boris P. Sokolov, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5217A, MSC 7846, Bethesda, MD 20892, 301–435– 1197, bsokolov@csr.nih.gov. Name of Committee: Integrative, Functional and Cognitive Neuroscience Integrated Review Group; Cognitive Neuroscience Study Section. Date: September 25, 2008. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Hilton Washington Embassy Row, 2015 Massachusetts Avenue, NW., Washington, DC 20036. Contact Person: Judith A. Finkelstein, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5178, MSC 7844, Bethesda, MD 20892, 301–435– 1249, finkelsj@csr.nih.gov. E:\FR\FM\31JYN1.SGM 31JYN1

Agencies

[Federal Register Volume 73, Number 148 (Thursday, July 31, 2008)]
[Notices]
[Pages 44754-44755]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-17508]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Methods for Promoting Stem Cell Proliferation and Survival

    Description of Technology: Regenerative medicine has the potential 
to treat numerous human diseases and afflictions including 
neurodegenerative disorders and spinal cord injury that are typically 
insidious and worsen over time. This technology consists of a promising 
treatment method that coaxes stem cells into a state that promotes 
survival and proliferation. Two critical elements of this approach 
involve identifying the target niche and determining the 
pharmacological agents that can be used to promote stem cell 
regeneration.
    Specifically, this technology consists of a method to activate the 
endogenous neural stem cells (NSCs) to promote their survival and yield 
using angiopoietin-2 and a cocktail of ligands and growth factors. This 
method has demonstrated that it can significantly improve the yield of 
stem cell cultures in vitro and stimulate behavioral recovery in a 
model of Parkinson's disease in vivo. This method is applicable to a 
variety of stem cell types including embryonic stem cells, adult spinal 
cord cells, and pericyctes from blood vessels.
    Possible Applications:
     Method for culturing stem cells for optimal regeneration.
     Treatment of neurological diseases and disorders such as 
Parkinson's disease, stroke, diabetes-related neuropathies, and spinal 
cord.
     Diagnostic assays to determine proliferation or inhibition 
of stem cells.
    Development Status: Pre-clinical.
    Inventors: Andreas Androutsellis-Theotokis and Ronald D.G. McKay 
(NINDS).
    Relevant Publication: A Androutsellis-Theotokis, RR Leker, F 
Soldner, DJ Hoeppner, R Ravin, SW Poser, MA Rueger, SK Bae, R Kittappa, 
RD McKay. Notch signaling regulates stem cell numbers in vitro and in 
vivo. Nature. 2006 Aug 17;442(7104):823-826.
    Patent Status: U.S. Provisional Application No. 60/965,094 filed 16 
Aug 2007 (HHS Reference No. E-182-2007/0-US-01)
    Licensing Status: Available for licensing.
    Licensing Contact: Fatima Sayyid, M.H.P.M.; 301-435-4521; 
Fatima.Sayyid@nih.hhs.gov
    Collaborative Research Opportunity: The National Institute of 
Neurological Disorders and Stroke is seeking statements of capability 
or interest from parties interested in collaborative research to 
further develop, evaluate, or commercialize agents with activity on 
proliferation and/or differentiation of stem cells. Please contact 
Laurie Arrants at 301-435-3112 or ArrantsL@ninds.nih.gov or Martha 
Lubet at 301-435-3120 or lubetm@mail.nih.gov for more information.

Treatment of Alcoholism by Inhibition of the Neuropeptide Y Receptor

    Description of Technology: Aversive or anticraving medications are 
currently used to supplement behavioral treatment of alcohol 
dependence. However, there is a need for developing more effective 
medications than those available. Neuropeptide Y (NPY) is a 
neurotransmitter known for increasing appetite and possibly having a 
role in alcohol preference and dependence. This is likely to be 
mediated by activation of the post-synaptic NPY-Y1 receptor, but 
developing molecules suitable for human therapeutics that activate that 
receptor represents a major challenge. Researchers at the NIH have now 
shown that administering antagonists of the presynaptic Y2 receptor of 
NPY decreases alcohol consumption and may be a valuable new treatment 
for alcoholism.
    Applications: Treatment of alcohol dependence.
    Market: In the United States, 17.6 million people--about l in every 
12 adults--abuse alcohol or are alcohol dependent. It is estimated that 
on any given day, more than 700,000 people in the United States receive 
alcoholism treatment. Consequently, billions of dollars are spent in 
the treatment, prevention, and support of persons suffering from 
alcoholism. Moreover, the economic loss attributed to alcohol abuse and 
alcoholism is in the trillions.
    Development Status: Early stage.
    Inventors: Markus Heilig (NIAAA) et al.
    Publications:
    1. R Rimondini et al. Suppression of ethanol self-administration by 
the neuropeptide Y (NPY) Y2 receptor antagonist BIIE0246: Evidence for 
sensitization in rats with a history of dependence. Neurosci Lett. 2005 
Feb 28;375(2):129-133.
    2. A Thorsell et al. Blockade of central neuropeptide Y (NPY) Y2 
receptors reduces ethanol self-administration in rats. Neurosci Lett. 
2002 Oct 25;332(1):1-4.
    Patent Status: U.S. Patent Application 10/492,785 filed 17 May 2004 
(HHS Reference No. E-101-2004/0-US-03); Swedish Patent Application 
0103476-8 filed 18 Oct 2001 (HHS Reference No. E-101-2004/0-SE-01)
    Licensing Status: Available for licensing.
    Licensing Contact: Norbert Pontzer, JD, PhD; 301-435-5502; 
pontzern@mail.nih.gov.
    Collaborative Research Opportunity: The National Institute on 
Alcohol Abuse and Alcoholism, Laboratory of Clinical and Translational 
Studies is seeking

[[Page 44755]]

statements of capability or interest from parties interested in 
collaborative research to further develop, evaluate, or commercialize 
antagonism of presynaptic NPY Y2 receptors for treatment of alcohol 
dependence. Please contact Peter B. Silverman at psilverm@mail.nih.gov 
for more information.

    Dated: July 22, 2008.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. E8-17508 Filed 7-30-08; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.